原发性肝细胞肝癌(HCC)的放化疗敏感性差，探索有效的HCC新型靶点是其基因治疗的关键点。miR-199a*与HCC的关系日益受到关注, HCC的发生发展伴随其低表达，而外源导入miR-199a*则可抑制肝癌细胞增殖；另发现其还可抑制HCV复制，而HCV持续感染与肝癌相关，因此其有望作为肝癌防治的新靶点。基因治疗的另一关键问题是载体选择，间充质干细胞(MSCs)作为一类新型的基因治疗运载系统具有高效、安全、肿瘤靶向性等诸多优点。表达特定抗癌基因的骨髓MSC用于肿瘤靶向治疗已取得了一些进展。而成体脂肪MSC(AMSC)作为一类可重复获取、供者不适度低的干细胞将更具前景。我们已发现导入miR-199a*的AMSC可有效抑制肝癌细胞增殖，因此本项目拟进一步明确AMSC-miR-199*在体内外的抗肿瘤和抗病毒疗效和机制，从而为临床应用表达miR-199*的AMSC进行肝癌靶向治疗提供理论依据。

The sensitivity of primary hepatocellular carcinoma (HCC) to the radiotherapy and chemotherapy is low, therefore, it is critical for us to explore the new effective target points for gene therapy. Recently, much attention to the relationship between miR -199a* and HCC has been paid. miR -199a* expresses at low level during the development of HCC, but the exogenous miR -199a* can inhibit the proliferation of hepatoma cells. Also miR -199a* can suppress the replication of HCV, which is accociated with HCC. So miR -199a* may be a promising candidate target for HCC treatment. Selection of optimal vector is another important issue for gene therapy. MSC, as new vector for gene therapy, has been recognized as a safe, highly efficient and tumor-specific vector. Several studies have confirmed that MSCs carrying anti-tumor genes could be used for treating cancers. Among various types of MSCs, human adipose tissue-derived MSCs (AMSC) serve as one of the most attractive vehicles for gene therapy because of their high throughput, lack of ethical concerns, and availability and ease of isolation.We found that the proliferation of hepatoma cells was markedly suppressed by introduction of AMSC carrying miR -199a*. Therefore, the aims of present study are to investigate the mechanisms underlying the anti-tumor and anti-viral effects of AMSC-carrying miR -199a* and to provide the theoretical base for this treatment of HCC.